Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumors|Breast Cancer
Interventions: DRUG: Tanespimycin
Sponsor: Bristol-Myers Squibb